|
FTC’s Silence Threatens GPhA Third-Party Shortages Plan
The Federal Trade Commission (FTC) may not issue the advisory opinion the generic drug industry is waiting for before launching its third-party drug shortage program, possibly derailing the initiative.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives